



Allogeneic CAR T

-  • Can be manufactured at larger scale
- Ready when the patient needs treatment
- Off-the-Shelf therapy allows for more uniformity of product & faster delivery to patients while driving down costs

-  • Potential risk for Graft-versus-Host & Host-versus-Graft complications stemming from treatment due to alloreactivity



Off-the-Shelf Approach
(Treatment ready to use when needed)

CAR T cells are prepared in advance from healthy donors




Step 1
Cells harvested from healthy donor's blood

Step 2
Cells engineered

Step 3
Modified T cells become CAR T cells

Step 4
CAR T cells are expanded & frozen for shipment

Step 5
CAR T cells infused into a cancer patient



Autologous CAR T

- + • Tailor-made for an individual's cancer
- Minimal risk of rejection of cells or alloreactivity since CAR T cells are derived from the patient's own cells
- • Not appropriate for large batch production due to manufacturing capacity constraints
- Weeks needed between diagnosis & patient treatment, limiting use to cancers that aren't rapidly progressing



A Personalized Approach
(Treatment custom made for an individual)

CAR T cells from patients themselves,
Engineered then **reintroduced to the patient**

